Navigation Links
Replidyne to Report First Quarter 2008 Earnings
Date:4/29/2008

LOUISVILLE, Colo., April 29 /PRNewswire-FirstCall/ -- Replidyne, Inc. (Nasdaq: RDYN) announced today that it will hold a conference call on Wednesday, May 7, 2008 at 4:45 P.M. ET to report first quarter 2008 earnings. On Thursday, May 8, 2008 at 4:00 P.M. ET Replidyne will host its annual shareholder meeting at Company headquarters at 1450 Infinite Drive in Louisville, CO.
Earnings conference call information is as follows:

Kenneth J. Collins, President and CEO, and other members of Replidyne's

management team will discuss earnings results via conference call and

webcast on Wednesday, May 7, 2008, at 4:45 P.M. ET. Callers may

participate in the conference call by dialing 866-770-7125 (domestic) or

617-213-8066 (international), and providing the passcode 79991920. To

access the live webcast, please log on to the Company's website at

http://www.Replidyne.com and go to the Investor Relations section.

A replay of the conference call will be available approximately one hour

after completion of the call through Wednesday, May 21, 2008 at

midnight. Callers may access the replay by dialing 888-286-8010 (U.S.

participants) or 617-801-6888 (international participants). The audio

replay passcode is 81984297. To access a replay of the webcast, visit

the Investor Relations section of the Company's website at

http://www.Replidyne.com.

About Replidyne, Inc.

Replidyne is a biopharmaceutical company focused on discovering, developing, in-licensing and commercializing innovative anti-infective products. Replidyne's most advanced product candidate, faropenem medoxomil, is a novel oral community antibiotic, expected to be appropriate for use as a first-line antibiotic for treatment of respiratory and skin infections in adult and pediatric patients. Replidyne's investigational antibacterial agent REP3123 targets Gram-positive C. difficile bacteria and C. difficile Infection (CDI). Replidyne is pursuing the development of other novel anti-infective programs based on its DNA replication inhibition technology and its in-house discovery research.

Safe Harbor

This press release contains plans, intentions, objectives, estimates and expectations that constitute forward-looking statements about Replidyne, Inc. that involve significant risks and uncertainties. Actual results could differ materially from those discussed due to a number of factors including, the success and timing of pre-clinical studies and clinical trials; the Company's ability to obtain a new partner for faropenem on acceptable terms; the Company's ability to obtain and maintain regulatory approval of product candidates and the labeling under any approval that may be obtained; plans to develop and commercialize product candidates; the loss of key scientific or management personnel; the size and growth of the potential markets for the Company's product candidates and the Company's ability to serve those markets; regulatory developments in the U.S. and foreign countries; the rate and degree of market acceptance of any future products; the accuracy of Company estimates regarding expenses, future revenues and capital requirements; the Company's ability to obtain and maintain intellectual property protection for our product candidates; the successful development of the Company's sales and marketing capabilities; the success of competing drugs that are or become available; and the performance of third party manufacturers. These and additional risks and uncertainties are described more fully in the Company's most recent Form 10-K filed with the SEC under the Securities Exchange Act of 1934. Copies of filings made with the SEC are available through the SEC's electronic data gathering analysis and retrieval system (EDGAR) at http://www.sec.gov. All forward-looking statements made in the press release are made as of the date hereof and the Company assumes no obligation to update the forward-looking statements in the document.


'/>"/>
SOURCE Replidyne, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Replidyne to Announce Third Quarter 2007 Earnings
2. Replidyne to Report 2007 Fourth Quarter and Year-End Earnings
3. Replidyne Announces 2007 Fourth Quarter and Full Year Results
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. QMed, Inc. Reports July Medicare SNP Enrollments
6. Phlo Affiliate Reports Expanded Coverage to Oregon Border
7. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
8. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
9. Carrington Reports Second Quarter 2007 Results
10. Avitar Reports Third Quarter Financial Results for Fiscal 2007
11. Response Genetics Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... -- Research and Markets has announced the addition of ... their offering. ... The report provides separate comprehensive analytics for the US, ... World. Annual estimates and forecasts are provided for the period 2015 ... markets. Market data and analytics are derived from primary and secondary ...
(Date:2/17/2017)...  If only one in every hundred cells ... to chemotherapy, thousands of cancer cells would remain ... finding these mutations in ever-smaller subpopulations of tumor ... in blood — to guide treatment decisions and ... however, detecting these genetic anomalies may be more ...
(Date:2/16/2017)... ... ... EIT Digital has launched work to develop a new Smart IOT ... to get under way for the framework, which is designed to reduce the use ... to be transferred eventually to other industries that also require efficient IoT and management ...
(Date:2/16/2017)... PARK, Calif. and GREENWICH, ... Capital, a private investment firm focused on venture ... announced the promotion of Josh Richardson , ... focuses on investments in biotechnology companies.  He is ... has played important roles in Longitude,s investments in ...
Breaking Biology Technology:
(Date:2/2/2017)... YORK , Feb. 2, 2017  EyeLock LLC, ... released a new white paper " What You Should ... The problem of ensuring user authenticity is a growing ... the authentication of users. However, traditional authentication schemes such ... Biometric authentication offers an elegant solution ...
(Date:1/30/2017)... Jan. 30, 2017   Invitae Corporation (NYSE: ... genetic information companies, today announced that it will report ... provide 2017 guidance on Monday, February 13, 2017, and ... day at 4:45 p.m. Eastern / 1:45 p.m. Pacific. ... will briefly review financial results, guidance, and recent developments ...
(Date:1/24/2017)... Biopharm Reports has carried out a ... nuclear magnetic resonance spectroscopy (NMR). This involved the ... practices, developments, trends and end-user plans over the ... opportunities. These areas include growth in the use ... innovation requirements, hyphenated NMR techniques, main suppliers of ...
Breaking Biology News(10 mins):